Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug ...

Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 185 % ...

As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is ...

CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $460.0 for Vertex Pharmaceuticals, spanning the last ...

At 22, Daniel Cressy is making history as Louisiana’s first sickle cell gene therapy patient. The treatment could be a cure ...